254 related articles for article (PubMed ID: 2741811)
1. Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Kuchar DL; Garan H; Venditti FJ; Finkelstein D; Rottman JN; McComb J; McGovern BA; Ruskin JN
Am J Cardiol; 1989 Jul; 64(1):33-6. PubMed ID: 2741811
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease.
Young GD; Kerr CR; Mohama R; Boone J; Yeung-Lai-Wah JA
Am J Cardiol; 1994 Apr; 73(9):677-82. PubMed ID: 8166065
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
Haverkamp W; Martinez-Rubio A; Hief C; Lammers A; Mühlenkamp S; Wichter T; Breithardt G; Borggrefe M
J Am Coll Cardiol; 1997 Aug; 30(2):487-95. PubMed ID: 9247523
[TBL] [Abstract][Full Text] [Related]
4. [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
Trappe HJ; Klein H; Lichtlen PR
Z Kardiol; 1987 Oct; 76(10):630-4. PubMed ID: 3687165
[TBL] [Abstract][Full Text] [Related]
5. Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias.
Hoppe UC; Haverkamp W; Breithardt G; Borggrefe M
Pacing Clin Electrophysiol; 2000 May; 23(5):854-62. PubMed ID: 10833706
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
Nademanee K; Feld G; Hendrickson J; Singh PN; Singh BN
Circulation; 1985 Sep; 72(3):555-64. PubMed ID: 4017207
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias.
Gonzalez R; Scheinman MM; Herre JM; Griffin JC; Sauve MJ; Sharkey H
J Am Coll Cardiol; 1988 Dec; 12(6):1568-72. PubMed ID: 3192854
[TBL] [Abstract][Full Text] [Related]
8. Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
Mewis C; Kühlkamp V; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jun; 33(7):1989-95. PubMed ID: 10362204
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
Steinbeck G; Bach P; Haberl R
J Am Coll Cardiol; 1986 Oct; 8(4):949-58. PubMed ID: 3760368
[TBL] [Abstract][Full Text] [Related]
10. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
Nademanee K; Singh BN
Am J Cardiol; 1990 Jan; 65(2):53A-57A; discussion 65A-66A. PubMed ID: 2403735
[TBL] [Abstract][Full Text] [Related]
11. Sotalol in patients with life-threatening ventricular tachyarrhythmias.
Trappe HJ; Klein H; Lichtlen P
Cardiovasc Drugs Ther; 1990 Oct; 4(5):1425-32. PubMed ID: 2278875
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
[TBL] [Abstract][Full Text] [Related]
13. Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
Jordaens LJ; Palmer A; Clement DL
Eur Heart J; 1989 Mar; 10(3):218-26. PubMed ID: 2707270
[TBL] [Abstract][Full Text] [Related]
14. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
[TBL] [Abstract][Full Text] [Related]
15. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest.
Singh SN; Cohen A; Chen YW; Wish M; Thoben-O'Grady L; Peralba J; Gottdiener J; Fletcher RD
Am J Cardiol; 1988 Sep; 62(7):399-402. PubMed ID: 2458026
[TBL] [Abstract][Full Text] [Related]
16. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
[TBL] [Abstract][Full Text] [Related]
17. Response to sotalol predicts the response to amiodarone during serial drug testing in patients with sustained ventricular tachycardia and coronary artery disease.
Martínez-Rubio A; Shenasa M; Chen X; Wichter T; Breithardt G; Borggrefe M
Am J Cardiol; 1994 Feb; 73(5):357-60. PubMed ID: 7509121
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
Kus T; Campa MA; Nadeau R; Dubuc M; Kaltenbrunner W; Shenasa M
Am Heart J; 1992 Jan; 123(1):82-9. PubMed ID: 1729853
[TBL] [Abstract][Full Text] [Related]
19. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease.
Böcker D; Haverkamp W; Block M; Borggrefe M; Hammel D; Breithardt G
Circulation; 1996 Jul; 94(2):151-7. PubMed ID: 8674173
[TBL] [Abstract][Full Text] [Related]
20. Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction.
Koch KT; Düren DR; van Zwieten PA
Cardiovasc Drugs Ther; 1995 Jun; 9(3):437-43. PubMed ID: 8527354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
